IL-17 axis targeting shows substantial efficacy but faces cost and delivery hurdlesIL-17 blockers show promise for autoimmune diseases

This systematic review synthesizes evidence on targeting the IL-17 axis across several immune-mediated and malignant conditions, including psoriasis, systemic lupus erythematosus, periodontitis, and cancer. The authors focus on two therapeutic modalities: monoclonal antibodies directed at IL-17 or its receptor, and small-molecule inhibitors. The review does not report a pooled effect size or specific trial data; instead, it provides a qualitative synthesis of the field.

The central finding is that monoclonal antibodies targeting IL-17 or its receptor have demonstrated substantial clinical efficacy. However, the authors emphasize several limitations that hinder their broader use: high cost, suboptimal tissue penetration, potential immunogenicity, and therapy-associated adverse effects. These factors are presented as key barriers to optimal patient outcomes.

The review does not report specific efficacy numbers, patient populations, or adverse event rates. It also does not describe the comparator or follow-up duration. The authors do not provide a certainty assessment or causality note, so the strength of the underlying evidence is not explicitly graded.

Despite these gaps, the review offers a framework for the rational design and development of next-generation IL-17-targeted therapeutics. It suggests that addressing the identified limitations could improve the clinical utility of this approach. Clinicians should interpret the efficacy claims cautiously, given the lack of quantitative detail and the acknowledged drawbacks.